Economic Burden and Quality of Life of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study

Layer, Peter; Andresen, Viola; Diemert, Sebastian; Mackinnon, J; Bertsch, Jordan; Fortea, J; Tack, Jan

doi:10.1016/j.jval.2015.09.2193

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IBS: irritable bowel syndrome; SD: standard deviation. (28). Over half of the patients observed some, little or no improvement of IBS as a result of their treatment.…”

Section: Discussionmentioning

confidence: 99%

Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Mira¹,

Lacima²,

Gil³

2018

Rev Esp Enferm Dig

View full text Add to dashboard Cite

show abstract

“…IBS: irritable bowel syndrome; SD: standard deviation. (28). Over half of the patients observed some, little or no improvement of IBS as a result of their treatment.…”

Section: Discussionmentioning

confidence: 99%

Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Mira¹,

Lacima²,

Gil³

2018

Rev Esp Enferm Dig

View full text Add to dashboard Cite

show abstract

“…13,[15][16][17]19 Subsequently, IBS-related symptoms result in increased family healthcare expenses, missed time from school, decreased quality of life, and associated anxiety and emotional stress for pediatric patients with IBS. 1,3,4,15,20,21 All of these negative consequences may extend into adulthood if an appropriate treatment is not identified.…”

Section: Introductionmentioning

confidence: 99%

Elimination of Fermentable Carbohydrates to Reduce Gastrointestinal Symptoms in Pediatric Patients With Irritable Bowel Syndrome: A Narrative Review

2019

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is classified as a functional gastrointestinal (GI) disorder characterized by abdominal pain, bloating, and changes in bowel function. Although the pathophysiology of IBS is incompletely understood, fermentable carbohydrates are implicated as a potential cause of symptoms. An elimination diet, such as a low‐FODMAP (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet, represents a potential intervention for reducing GI symptoms in patients with IBS. The role of fermentable carbohydrates in symptom onset is well studied in adult patients with IBS; however, less research exists in the pediatric population. This review sought to explore evidence for the role of dietary fermentable carbohydrate elimination to reduce GI symptoms (abdominal pain, stool changes, abdominal bloating) in children and adolescents (4–19 years of age) diagnosed with IBS based on Rome III or IV criteria. Five studies of neutral to positive quality rating were identified and analyzed using the Academy of Nutrition and Dietetics Evidence Analysis Process. These studies demonstrate that dietary elimination of fermentable carbohydrates, such as through a low‐FODMAP diet, reduces the severity of 1 or more GI symptoms in about one‐quarter to one‐half of pediatric patients with IBS. Patients without improvement are considered “nonresponders” and may require an alternative intervention. More research is needed to establish the best way to identify patients who would respond to elimination diets vs other IBS treatment strategies.

show abstract

“…IBS considerably affects quality of life and imposes a profound burden on patients, physicians and the health-care system[ 5 ]. For example, the IBIS-C study recently assessed the socio-economic burden of moderate-to-severe IBS with constipation in six European countries (France, Germany, Italy, Spain, Sweden and the United Kingdom), showing that IBS represents a main cause of absenteeism in the workplace[ 6 ].…”

Section: Introductionmentioning

confidence: 99%

New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond

Sinagra¹,

Morreale²,

Mohammadian³

et al. 2017

WJG

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) is a chronic, recurring, and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain, distention, and changes in bowel habits. Although there are several drugs for IBS, effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed. Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism, neurohormonal regulation, immune dysfunction, the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS. With regards to therapies for restoring intestinal permeability, multiple studies with prebiotics and probiotics are ongoing, even if to date their efficacy has been limited. In parallel, much progress has been made in targeting low-grade inflammation, especially through the introduction of drugs such as mesalazine and rifaximin, even if a better knowledge of the mechanisms underlying the low-grade inflammation in IBS may allow the design of clinical trials that test the efficacy and safety of such drugs. This literature review aims to summarize the findings related to new and investigational therapeutic agents for IBS, most recently developed in preclinical as well as Phase 1 and Phase 2 clinical studies.

show abstract

Economic Burden and Quality of Life of Moderate-To-Severe Irritable Bowel Syndrome With Constipation (Ibs-C) In Germany: Results From The Ibis-C Study

Cited by 6 publications

References 0 publications

Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Perceptions of the public healthcare system from private-care patients with irritable bowel syndrome with constipation in Spain

Elimination of Fermentable Carbohydrates to Reduce Gastrointestinal Symptoms in Pediatric Patients With Irritable Bowel Syndrome: A Narrative Review

New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond

Contact Info

Product

Resources

About